Journal article icon

Journal article

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.

Abstract:
In this review, we outline the pathophysiology of severe asthma and discuss the role of anti-interleukin (IL)-5 inhibitors for the treatment of asthma. Anti-IL-5 treatments have shown efficacy in reducing the rate of severe asthma attacks in eosinophilic asthma. We review the history of the development of these agents, lessons learnt about severe asthma along the way and key clinical trials supporting efficacy of the three anti-IL-5 treatments that are clinically available or undergoing clinical trials in asthma.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1007/s40259-017-0215-8

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Oxford college:
St Edmund Hall
Role:
Author
Publisher:
Springer Publisher's website
Journal:
BioDrugs Journal website
Volume:
31
Issue:
2
Pages:
93-103
Publication date:
2017-04-01
DOI:
EISSN:
1179-190X
ISSN:
1173-8804
Source identifiers:
689189
Language:
English
Keywords:
Pubs id:
pubs:689189
UUID:
uuid:5b2bc8d5-734d-4ef9-853e-678446b996dc
Local pid:
pubs:689189
Deposit date:
2017-05-11

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP